All patients | | |
n | 120 | 120 |
PSA (μg/mL) | 11.6 (0.1–558) | 12.0 (0.1–577) |
Primary staging | | |
n | 69 | 69 |
PSA (μg/mL) | 14.8 (3.2–558) | 14.7 (2.4–577) |
Gleason score* | | |
≤7a | 17 | 8 |
≥7b | 51 | 58 |
Unknown | 1 | 4 |
T stage† | | |
T1 | 23 | 15 |
T2 | 25 | 27 |
T3 | 16 | 22 |
T4 | 0 | 4 |
Unknown | 5 | 1 |
Androgen deprivation therapy | 0 | 0 |
Biochemical recurrence | | |
n | 21 | 21 |
PSA (μg/mL) | 2.4 (0.4–7.9) | 2.4 (0.4–7.8) |
Previous therapy | | |
Prostatectomy | 7 | 7 |
Radiation therapy | 12 | 12 |
Brachytherapy | 2 | 2 |
Androgen deprivation therapy‡ | 1 | 2 |
Follow-up systemic treatment | | |
n | 30 | 30 |
PSA (μg/mL) | 24.8 (0.1–385.0) | 26.3 (0.1–369.0) |
Androgen deprivation therapy | 30 | 30 |